Elwood & Goetz Wealth Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 867 shares of the medical research company’s stock, valued at approximately $536,000.
Other institutional investors have also made changes to their positions in the company. Signature Resources Capital Management LLC boosted its position in Thermo Fisher Scientific by 318.2% in the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. New Millennium Group LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at approximately $29,000. Stephens Consulting LLC grew its position in Thermo Fisher Scientific by 116.0% during the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after acquiring an additional 29 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Thermo Fisher Scientific in the first quarter worth about $32,000. Finally, Bank & Trust Co acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $33,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $76,420,473.36. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 6,300 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,548,375.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Research Report on TMO
Thermo Fisher Scientific Price Performance
NYSE:TMO opened at $554.38 on Friday. The stock’s 50-day simple moving average is $605.12 and its 200 day simple moving average is $584.04. Thermo Fisher Scientific Inc. has a 52-week low of $420.21 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. The company has a market cap of $211.77 billion, a P/E ratio of 34.39, a P/E/G ratio of 3.75 and a beta of 0.77.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.69 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
- Five stocks we like better than Thermo Fisher Scientific
- What is a Stock Market Index and How Do You Use Them?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- 3 Stocks to Consider Buying in October
- MarketBeat Week in Review – 10/21- 10/25
- Breakout Stocks: What They Are and How to Identify Them
- Texas Roadhouse Stock Steering for New Highs This Year
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.